Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITRINE real-world study of AbbVie regimen for chronic hepatitis C
MOH_2017-02-12_000099Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin in hepatitis C virus infection (4 arms), sponsored by AbbVie Inc. Started Jun 2016; status: completed.
02
Drugs
paritaprevirritonavirombitasvirdasabuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on MOH_2017-02-12_000099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-12_000099.